<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25827" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hammi</surname>
            <given-names>Claudia</given-names>
          </name>
          <aff>UC Irvine Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yeung</surname>
            <given-names>Brent</given-names>
          </name>
          <aff>UC Irvine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Claudia Hammi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brent Yeung declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25827.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>About 2.4% of the population is affected by peripheral neuropathy. The prevalence increases to 8%&#x000a0;in older populations. Peripheral neuropathy can be a manifestation of a wide range of pathologies that require further evaluation or treatment. Furthermore, peripheral neuropathies must be addressed before they result in complications, such as falls with subsequent hip fractures or pedal infections necessitating amputation. Interprofessional team members must recognize and evaluate peripheral neuropathy so that any underlying cause can be addressed and complications can be prevented, improving patient outcomes. This activity highlights considerations when evaluating and treating patients with peripheral neuropathies and demonstrates the critical role that interprofessional care teams play in caring for patients suffering from peripheral neuropathies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of peripheral neuropathy.</p></list-item><list-item><p>Determine&#x000a0;the appropriate evaluation of a patient with peripheral neuropathy.</p></list-item><list-item><p>Assess the treatment and management options available for peripheral neuropathy.</p></list-item><list-item><p>Communicate the importance of improving care coordination amongst the interprofessional team to enhance care delivery for patients with peripheral neuropathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25827">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25827.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Peripheral neuropathies encompass disorders of peripheral nerve cells and fibers, manifesting secondary to a wide range of pathologies. These include cranial nerves, spinal nerve roots&#x000a0;and&#x000a0;ganglia, nerve trunks&#x000a0;and division, and autonomic nervous system nerves.<xref ref-type="bibr" rid="article-25827.r1">[1]</xref>&#x000a0;Several methods classify peripheral neuropathies, including mononeuropathies, multifocal neuropathies, and polyneuropathies. Further subclassifications can be made by separating peripheral neuropathies as axonal, demyelinating, or mixed, essential for treatment and management.<xref ref-type="bibr" rid="article-25827.r2">[2]</xref> The most frequently encountered symptoms of&#x000a0;peripheral neuropathy include numbness and paresthesias; pain, weakness, and loss of deep tendon reflexes may accompany these symptoms. Peripheral neuropathies usually develop over months to years, while some may develop more rapidly and be progressive. Peripheral neuropathies have a broad range of severity and clinical manifestations, as&#x000a0;they can affect motor, sensory, and autonomic fibers.</p>
      </sec>
      <sec id="article-25827.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Peripheral neuropathies stem from a variety of origins, including metabolic, systemic, and toxic causes. Underlying etiologies to consider include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Chronic alcoholism</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiencies (eg, B1, B6, B12, and vitamin E)</p>
          </list-item>
          <list-item>
            <p>Inflammatory conditions (eg, vasculitis)</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Autoimmune disease (eg, Sj&#x000f6;gren syndrome, lupus, rheumatoid arthritis)</p>
          </list-item>
          <list-item>
            <p>Infections (eg, Lyme disease, Epstein-Barr virus, hepatitis C, shingles, leprosy, HIV)</p>
          </list-item>
          <list-item>
            <p>Guillain-Barre syndrome</p>
          </list-item>
          <list-item>
            <p>Toxins (heavy metals, chemicals)</p>
          </list-item>
          <list-item>
            <p>Chemotherapy agents</p>
          </list-item>
          <list-item>
            <p>Medications (antibiotics, cardiovascular medications)</p>
          </list-item>
          <list-item>
            <p>Tumors (secondary to compression or associated paraneoplastic syndromes)</p>
          </list-item>
          <list-item>
            <p>Inherited conditions&#x000a0;(eg, Charcot-Marie-Tooth disease, familial amyloidosis)</p>
          </list-item>
          <list-item>
            <p>Trauma or injury</p>
          </list-item>
          <list-item>
            <p>Multiple myeloma and its treatments</p>
          </list-item>
          <list-item>
            <p>Monoclonal gammopathy of undetermined significance (MGUS)</p>
          </list-item>
        </list>
        <p>In some cases, a direct cause may not be apparent.</p>
      </sec>
      <sec id="article-25827.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>About 2.4% of the world population is affected by peripheral nerve disorders; the prevalence increases to 8% in older populations.<xref ref-type="bibr" rid="article-25827.r3">[3]</xref>&#x000a0;Diabetic neuropathy occurs in approximately half of individuals with chronic type 1 and type 2 diabetes. Globally, leprosy remains a common cause of peripheral neuropathy, with the highest prevalence in Southeast Asia.</p>
        <p>The most common genetic sensorimotor polyneuropathy is&#x000a0;Charcot-Marie-Tooth disease, specifically, type 1a. The most common mononeuropathy is carpal tunnel syndrome.&#x000a0;</p>
      </sec>
      <sec id="article-25827.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathophysiology of peripheral neuropathy depends on the underlying disease. Although a wide assortment of distinct diseases can ultimately lead to peripheral neuropathies, the mechanisms by which peripheral nerves suffer injury exhibit similar patterns.&#x000a0;</p>
        <p>
<bold>Segmental&#x000a0;Demyelination </bold>
</p>
        <p>Segmental demyelination refers to the degeneration of the myelin sheath, with sparing of the nerve axon. This type of reaction can present in mononeuropathies, sensorimotor, or, principally, motor neuropathies. These are often inflammatory and sometimes&#x000a0;immune-mediated. About 20% of symmetrical peripheral neuropathies result from damage to the myelin.&#x000a0;Examples include Charcot-Marie-Tooth and neuropathy associated with monoclonal gammopathy of undetermined significance.</p>
        <p>
<bold>Wallerian Degeneration </bold>
</p>
        <p>Wallerian degeneration occurs after a nerve axon degenerates due to&#x000a0;a lesion or physical compression; the portion distal to the axon passively wastes away, likely due to a lack of nutrients from the cell body. This reaction results in focal mononeuropathy that is secondary to trauma or infarction of the nerve.<xref ref-type="bibr" rid="article-25827.r4">[4]</xref>&#x000a0;Wallerian degeneration is immunohistochemically distinct by the localization of neuropeptide Y-Y1 receptor markers.<xref ref-type="bibr" rid="article-25827.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Axonal Degeneration</bold>
</p>
        <p>Axonal degeneration, also known as the dying-back phenomenon: This type of degeneration usually manifests as symmetrical polyneuropathy (around 80%) and tends to cause weakness,&#x000a0;most notably weakness in dorsiflexion of the ankles and foot, with accompanied trophic changes to muscle. The axon degenerates in a pattern that starts distal and progresses proximally; this is thought to be because the most distal portion of the axon is particularly vulnerable&#x000a0;due to its distance from the cell body, which provides metabolic support.<xref ref-type="bibr" rid="article-25827.r6">[6]</xref>&#x000a0;A proposed mechanism is that&#x000a0;insult to the nerve causes impaired delivery of local axonal survival factors, resulting in an increased level of calcium intra-axonal, leading to&#x000a0;a calcium-dependent cytoskeletal breakdown.<xref ref-type="bibr" rid="article-25827.r7">[7]</xref> Examples of diseases causing axonal degeneration include diabetes, HIV,&#x000a0;hepatitis C virus, and Guillain-Barre syndrome.<xref ref-type="bibr" rid="article-25827.r8">[8]</xref></p>
      </sec>
      <sec id="article-25827.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of peripheral neuropathy widely varies depending on the underlying disease process. Patients may complain of symptoms initially starting in their digits and progressing to their proximal limbs. Symptoms range and include changes in sensation, weakness, atrophy, pain, numbness, and even autonomic disturbances. Clinically, these symptoms may resemble those of myelopathies, radiculopathies, autoimmune diseases, and diseases of muscles. Advanced disease may progress to reduced or absent deep tendon reflexes, stocking-glove pattern sensory loss, muscle wasting, and weakness.<xref ref-type="bibr" rid="article-25827.r3">[3]</xref>&#x000a0;Obtaining a thorough history is vital in helping to uncover the primary cause of neuropathy. Aside from a meticulous review of past medical history,&#x000a0;providers should inquire about toxic exposures, present and past medications, trauma, dietary and nutritional deficiencies, and alcohol use.</p>
      </sec>
      <sec id="article-25827.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating patients with neuropathy involves a detailed history and physical, including a review of current and past medications. Although there are no standard laboratory or imaging studies to test for peripheral neuropathies, the following studies may aid in the diagnosis and help narrow down the&#x000a0;underlying cause&#x000a0;of the&#x000a0;neuropathy (eg, inflammatory, infectious, metabolic): &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count (macrocytic anemia may clue the clinician to vitamin B12 or folate deficiency, or even alcohol abuse)</p>
          </list-item>
          <list-item>
            <p>Metabolic panels such as&#x000a0;basic metabolic panel or&#x000a0;complete metabolic panel (look for electrolyte imbalances contributing to neuropathy and renal failure as uremia can also lead to neuropathy).<xref ref-type="bibr" rid="article-25827.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Hemoglobin A1c Testing (Diabetes is a common cause of neuropathy)</p>
          </list-item>
          <list-item>
            <p>Testing for vitamin and mineral deficiencies such as copper, thiamine, pyridoxine, folate, B12, and vitamin E play fundamental roles in nervous system development and maintenance.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Heavy metal toxicities&#x000a0;such as mercury, lead, and arsenic are known to cause peripheral nerve toxicities along with CNS disturbances&#x000a0;<xref ref-type="bibr" rid="article-25827.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Infectious workup for Lyme disease, Epstein-Barr virus, hepatitis C, HIV, and syphilis as a long-standing disease may manifest with peripheral neuropathies and paresthesias&#x000a0;<xref ref-type="bibr" rid="article-25827.r10">[10]</xref><xref ref-type="bibr" rid="article-25827.r11">[11]</xref><xref ref-type="bibr" rid="article-25827.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Thyroid function testing<xref ref-type="bibr" rid="article-25827.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Antibody testing for specific autoimmune diseases known to cause peripheral neuropathies, such as Sj&#x000f6;gren syndrome, lupus, and rheumatoid arthritis&#x000a0;<xref ref-type="bibr" rid="article-25827.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Nerve conduction study and electromyography&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MRI or CT scans in cases where compression of the nerve is of concern</p>
          </list-item>
          <list-item>
            <p>Nerve biopsy</p>
          </list-item>
          <list-item>
            <p>Genetic testing (for inherited neuropathies)</p>
          </list-item>
          <list-item>
            <p>Urine Test (looking for Bence-Jones proteins as multiple myeloma and its treatments can cause peripheral neuropathy)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25827.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of peripheral neuropathies should focus on the treatment of the underlying disease process. For example, glucose control in diabetic neuropathy and alcohol cessation in alcoholic neuropathy. Nutritional deficiencies can be treated with the supplementation of depleted&#x000a0;vitamins or minerals. Unfortunately, not all peripheral neuropathies are reversible. Physical and occupational therapy can be initiated to aid in improving a patient's overall strength and function. Chronic inflammatory demyelinating&#x000a0;neuropathy is initially treated using corticosteroids but can also be treated using intravenous immunoglobulin, plasma exchange, and some immunosuppressant drugs.<xref ref-type="bibr" rid="article-25827.r15">[15]</xref></p>
        <p>A referral to a pain specialist can be beneficial for those patients who are suffering from neuropathic pain.&#x000a0;Neuropathic pain, particularly in those suffering from small-fiber neuropathies, does not typically respond to simple analgesics. Instead, effective treatment for pain associated with peripheral neuropathies can be with membrane stabilizers, certain anti-epileptics, and tricyclic antidepressants.<xref ref-type="bibr" rid="article-25827.r16">[16]</xref>&#x000a0;Transcutaneous electrical nerve stimulation (TENS) is also an option as a noninvasive intervention for pain relief.</p>
      </sec>
      <sec id="article-25827.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differentials to consider greatly&#x000a0;vary depending on clinical&#x000a0;presentation. Symptoms of peripheral neuropathies&#x000a0;may resemble those of myelopathies, radiculopathies, autoimmune diseases, and diseases of muscles.</p>
      </sec>
      <sec id="article-25827.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In those diseases where peripheral nerves suffer damage through Wallerian or axonal degeneration, the prognosis is poorer, as the recovery of the nerve is more challenging. The axon must regenerate itself and reinnervate the affected muscle or organ for clinical improvement. The prognosis of diseases that occur secondary to segmental demyelination is more favorable because remyelination is achieved more quickly, allowing the return of function of the axon.</p>
      </sec>
      <sec id="article-25827.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of peripheral neuropathies include pain, altered sensation, muscle atrophy, and weakness. Diabetic peripheral neuropathy is infamous for complications, including foot ulcers, which can lead to gangrenous digits and limbs, sometimes progressing to amputation.</p>
      </sec>
      <sec id="article-25827.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations and referrals to consider for patients suffering from peripheral neuropathy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurologist</p>
          </list-item>
          <list-item>
            <p>Chronic pain physician</p>
          </list-item>
          <list-item>
            <p>Physical therapy</p>
          </list-item>
          <list-item>
            <p>Occupational therapy</p>
          </list-item>
          <list-item>
            <p>Endocrinologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Rheumatologist</p>
          </list-item>
          <list-item>
            <p>Psychiatry and addiction medicine (for those with alcohol-induced&#x000a0;peripheral neuropathy)</p>
          </list-item>
          <list-item>
            <p>Infectious disease specialist</p>
          </list-item>
          <list-item>
            <p>Surgeon (for neuropathy secondary to compression)</p>
          </list-item>
          <list-item>
            <p>Hematology&#x000a0;or oncology (for those with neuropathy related to cancer)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25827.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients require education on the signs and symptoms of peripheral neuropathy. Patients should be made aware that they have an increased risk of injury due to loss of sensation; they should be&#x000a0;conscious of any new cuts or damage to their skin as wound healing&#x000a0;can be delayed, and the risk for infection increases. Recommend always wearing socks with&#x000a0;closed-toed shoes to decrease the risk of infection. Patients should take caution when exposing themselves to hot or cold environments to avoid burns and frostbite. Patients with diabetes should receive counseling on managing their diabetes appropriately. Patients with alcohol-induced&#x000a0;neuropathy should get information on cessation.</p>
      </sec>
      <sec id="article-25827.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Charcot-Marie-Tooth is the most commonly inherited cause of peripheral neuropathy&#x000a0;<xref ref-type="bibr" rid="article-25827.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Demyelinating neuropathies are commonly inflammatory and often treatable&#x000a0;<xref ref-type="bibr" rid="article-25827.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Neurophysiological tests can differentiate axonal from demyelinating neuropathies</p>
          </list-item>
          <list-item>
            <p>Overall, the most common polyneuropathy is diabetic sensorimotor polyneuropathy&#x000a0;<xref ref-type="bibr" rid="article-25827.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy can be divided into mono-neuropathies, multifocal neuropathies, and polyneuropathies, with further subclassifications into axonal, demyelinating, or mixed types.</p>
          </list-item>
          <list-item>
            <p>Neuropathic pain can be effectively treated with membrane stabilizers, certain antiepileptics, and tricyclic antidepressants</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25827.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A&#x000a0;wide range of disease processes can&#x000a0;lead to peripheral neuropathies, which routinely require an interprofessional team approach to diagnosis and treatment. This team should include physicians, specialists, specialty-trained nurses, and, when necessary, pharmacists, all working collaboratively to achieve optimal patient care and outcomes. Neuropathies can be both painful and debilitating for patients. Thus, it is vital to acquire a prompt diagnosis of the underlying condition followed by the initiation of appropriate treatment(s) to reverse, slow, or stop the progression of the disease. Identifying patients most at risk for neuropathies and implementing a preventative&#x000a0;approach to their care can undoubtedly improve&#x000a0;outcomes for patients, as seen in the case of diabetic neuropathy. As primary care providers and nurse practitioners are often the first to work with these patients, they must be familiar with the full range of etiologies that play a role in developing peripheral neuropathies, including testing and referrals to the appropriate specialists. &#x000a0;</p>
      </sec>
      <sec id="article-25827.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25827">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/nerve-health/neuropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25827">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25827/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25827">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25827.s17">
        <title>References</title>
        <ref id="article-25827.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remiche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kadhim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mavroudakis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience].</article-title>
            <source>Rev Med Brux</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>211</fpage>
            <page-range>211-20</page-range>
            <pub-id pub-id-type="pmid">24195230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanewinckel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ikram</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Van Doorn</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathies.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2016</year>
            <volume>138</volume>
            <fpage>263</fpage>
            <page-range>263-82</page-range>
            <pub-id pub-id-type="pmid">27637963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy.</article-title>
            <source>BMJ</source>
            <year>2002</year>
            <month>Feb</month>
            <day>23</day>
            <volume>324</volume>
            <issue>7335</issue>
            <fpage>466</fpage>
            <page-range>466-9</page-range>
            <pub-id pub-id-type="pmid">11859051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Signaling mechanisms regulating Wallerian degeneration.</article-title>
            <source>Curr Opin Neurobiol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>27</volume>
            <fpage>224</fpage>
            <page-range>224-31</page-range>
            <pub-id pub-id-type="pmid">24907513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dallenga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roemer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maruschak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stadelmann</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.</article-title>
            <source>J Neuroinflammation</source>
            <year>2017</year>
            <month>Mar</month>
            <day>17</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <pub-id pub-id-type="pmid">28302146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sumner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Asbury</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Physiological studies of the dying-back phenomenon. Muscle stretch afferents in acrylamide neuropathy.</article-title>
            <source>Brain</source>
            <year>1975</year>
            <month>Mar</month>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-100</page-range>
            <pub-id pub-id-type="pmid">164259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Medress</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Barres</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Axon degeneration: molecular mechanisms of a self-destruction pathway.</article-title>
            <source>J Cell Biol</source>
            <year>2012</year>
            <month>Jan</month>
            <day>09</day>
            <volume>196</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-18</page-range>
            <pub-id pub-id-type="pmid">22232700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cashman</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of distal axonal degeneration in peripheral neuropathies.</article-title>
            <source>Neurosci Lett</source>
            <year>2015</year>
            <month>Jun</month>
            <day>02</day>
            <volume>596</volume>
            <fpage>33</fpage>
            <page-range>33-50</page-range>
            <pub-id pub-id-type="pmid">25617478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staff</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Windebank</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy due to vitamin deficiency, toxins, and medications.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>5 Peripheral Nervous System Disorders</issue>
            <fpage>1293</fpage>
            <page-range>1293-306</page-range>
            <pub-id pub-id-type="pmid">25299283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halperin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Coyle</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Dattwyler</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Lyme disease: cause of a treatable peripheral neuropathy.</article-title>
            <source>Neurology</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1700</fpage>
            <page-range>1700-6</page-range>
            <pub-id pub-id-type="pmid">3670609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;&#x0015f;kderelio&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ortan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gedizlio&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Screening for Electrophysiological Abnormalities in Chronic Hepatitis C Infection: Peripheral Neuropathy and Optic Neuropathy.</article-title>
            <source>Noro Psikiyatr Ars</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-27</page-range>
            <pub-id pub-id-type="pmid">28360761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saylor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakigozi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nakasujja</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Wawer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>485</fpage>
            <page-range>485-491</page-range>
            <pub-id pub-id-type="pmid">28679596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karne</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bhalerao</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Carpal Tunnel Syndrome in Hypothyroidism.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>OC36</fpage>
            <page-range>OC36-8</page-range>
            <pub-id pub-id-type="pmid">27042500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkowitz</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis.</article-title>
            <source>Pract Neurol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">24307005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saperstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical spectrum of chronic acquired demyelinating polyneuropathies.</article-title>
            <source>Muscle Nerve</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-24</page-range>
            <pub-id pub-id-type="pmid">11353415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sindrup</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic treatment of pain in polyneuropathy.</article-title>
            <source>Neurology</source>
            <year>2000</year>
            <month>Oct</month>
            <day>10</day>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>915</fpage>
            <page-range>915-20</page-range>
            <pub-id pub-id-type="pmid">11061244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25827.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martyn</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of peripheral neuropathy.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>310</fpage>
            <page-range>310-8</page-range>
            <pub-id pub-id-type="pmid">9120441</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
